Key result
Vericiguat, a soluble guanylate cyclase stimulator, has shown add-on therapy efficacy by reducing morbidity and mortality in patients with worsening chronic heart failure.
Why the study?
Significant morbidity and mortality in patients with heart failure, notably in the most advanced forms, justify the need for novel therapeutic options.
Does vericiguat reduce morbidity and mortality in patients with worsening chronic heart failure?
Does vericiguat reduce morbidity and mortality in patients with worsening chronic heart failure?
Vericiguat acts as a novel sGC stimulator that complements current pharmacotherapy by reducing morbidity and mortality in patients with worsening chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Supports vericiguat add-on in worsening HF; leaves open need for confirmatory randomized trials.
Hulot et al. (2021) conducted a review in Worsening chronic heart failure. Vericiguat was evaluated. Vericiguat, a soluble guanylate cyclase stimulator, has shown add-on therapy efficacy by reducing morbidity and mortality in patients with worsening chronic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: